PARP inhibitors

On target clinical trial success bullseye score
Pharma

Pfizer eyes earlier Talzenna use after ph. 3 prostate cancer win

If approved, Talzenna would be the first PARP inhibitor to enter the HRR-mutant metastatic hormone-sensitive prostate cancer setting.
Angus Liu Mar 19, 2026 6:45am
ASCO

J&J PARP path unclear in castration-sensitive prostate cancer subset

Jun 3, 2025 8:00am
FDA

J&J, Pfizer and Roche face FDA questions over data applicability

May 16, 2025 3:52pm
Combine

Pfizer details survival win in bid for broad prostate cancer nod

Feb 13, 2025 10:00am
dart board miss failure

GSK trial result mirrors Merck's problem in ovarian cancer

Dec 20, 2024 10:46am
Pfizer

Pfizer targets broad Talzenna label in prostate cancer

Oct 10, 2024 10:18am